Although replacement FVIII therapy allows persons with HA (PHA) to have near normal life expectancies, the burden of disease continues to be high (2), and 30% of PHA develop anti-FVIII neutralizing antibodies (FVIII inhibitors), making replacement therapy ineffective and considerably increasing the risk of morbidity and mortality (3). Here, F8 is linked to Pelger-Huet anomaly.